White matter disease in cerebral organic acid disorders:: Clinical implications and suggested pathomechanisms

被引:32
作者
Kölker, S [1 ]
Mayatepek, E [1 ]
Hoffmann, GF [1 ]
机构
[1] Univ Heidelberg, Childrens Hosp, Dept Gen Pediat, Div Metab & Endocrine Dis, D-69120 Heidelberg, Germany
关键词
organic acid disorders; myelination; leukencephalopathy; excitotoxicity; glutamate receptors; reactive oxygen species;
D O I
10.1055/s-2002-36741
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
White matter abnormalities (including dys-, hypo-, demyelination and delayed myelation) are frequently found in cerebral organic acid disorders, a recently delineated subgroup of inherited organic acid disorders presenting predominantly with a neurological symptomatology. Biochemically, this disease subgroup lacks metabolic derangements, such as hypoglycemia, hyperammonemia and acidosis, and is characterized by an accumulation of organic acids that share structural similarities with the excitatory amino acid glutamate (D-2-, L-2-, 3-hydroxyglutarate, glutarate) or have been suggested as neurotransmitters/neuromodulators (N-acetylaspartylglutamate). Evidence from in vitro and in vivo studies is growing that relevant organic acids significantly contribute to the neuropathology of these diseases via interference with glutamatergic or GABAergic neurotransmission or impairment of energy metabolism. This article provides an overview on the clinical and neuroradiological presentation of white matter disease in cerebral organic acid disorders, focusing on the suggested pathomechanistic relevance of excitotoxicity, oxidative stress, and impaired energy metabolism.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 67 条
  • [1] ADACHI M, 1967, INBORN DISORDERS SPH, P129
  • [2] ALTERNATIVE EXCITOTOXIC HYPOTHESES
    ALBIN, RL
    GREENAMYRE, JT
    [J]. NEUROLOGY, 1992, 42 (04) : 733 - 738
  • [3] Back SA, 1998, J NEUROSCI, V18, P6241
  • [4] A CRUCIAL ROLE FOR NEUROTROPHIN-3 IN OLIGODENDROCYTE DEVELOPMENT
    BARRES, BA
    RAFF, MC
    GAESE, F
    BARTKE, I
    DECHANT, G
    BARDE, YA
    [J]. NATURE, 1994, 367 (6461) : 371 - 375
  • [5] L-2-HYDROXYGLUTARIC ACIDEMIA - CLINICAL AND BIOCHEMICAL FINDINGS IN 12 PATIENTS AND PRELIMINARY-REPORT ON L-2-HYDROXYACID DEHYDROGENASE
    BARTH, PG
    HOFFMANN, GF
    JAEKEN, J
    WANDERS, RJA
    DURAN, M
    JANSEN, GA
    JAKOBS, C
    LEHNERT, W
    HANEFELD, F
    VALK, J
    SCHUTGENS, RBH
    TREFZ, FK
    HARTUNG, HP
    CHAMOLES, NA
    SFAELLO, Z
    CARUSO, U
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 1993, 16 (04) : 753 - 761
  • [6] BEAL MF, 1993, J NEUROSCI, V13, P4181
  • [7] BEAUDET A, 2001, METABOLIC MOL BASES, P5799
  • [8] BRISMAR J, 1995, AM J NEURORADIOL, V16, P675
  • [9] BRISMAR J, 1990, AM J NEURORADIOL, V11, P805
  • [10] N-acetylaspartylglutamate in Canavan disease: an adverse effector?
    Burlina, AP
    Ferrari, V
    Divry, P
    Gradowska, W
    Jakobs, C
    Bennett, MJ
    Sewell, AC
    Dionisi-Vici, C
    Burlina, AB
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (05) : 406 - 409